REGULATION OF VESSEL REGRESSION IN ISCHEMIC RETINOPATHY

缺血性视网膜病变中血管退化的调节

基本信息

  • 批准号:
    7715979
  • 负责人:
  • 金额:
    $ 1.11万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-05-01 至 2009-04-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Retinopathy of prematurity (ROP) is a disorder of pathological retinal neovascularization, which can result in life-long blindness. The long-term goal of this project is to acquire a better understanding of the mechanisms surrounding retinal neovascularization in order to develop anti-angiogenesis therapies. We hypothesize that directly modulating pre-retinal endothelial cell (EC) apoptosis will be an efficient anti-angiogenic approach despite the multiple factors that can promote pathological angiogenesis. A novel class of signaling molecules, the ephrin/Eph receptors are also candidate molecules to regulate EC neovascularization and apoptosis. In order to test our hypothesis and identify mechanisms that are responsible for vascular tuft apoptosis, we propose the following specific Aims: 1) Identify specific death receptors that lead to EC apoptosis and promote tuft regression, specifically determine if direct activation of Fas will induce vessel regression; 2) Identify the contribution of microglia and macrophages to the regression of retinal neovascularization and their ability to induce apoptosis through the use of genetically altered mice; and 3) Further understand the role of ephrin/Eph receptors in retinal neovascularization by developing new therapeutic approaches to induce vessel regression, using soluble ligands to modulate the ephrin/Eph receptors in the mouse model of OIR.
这个子项目是众多研究子项目之一

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Charles T Roberts其他文献

ANP's Anti-hypertrophic Action Requires Activation of MEK and ERK and Is Raf Independent in Neonatal Rat Ventriculocytes
  • DOI:
    10.1203/00006450-199904020-00188
  • 发表时间:
    1999-04-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Michael Silberbach;Travis Gorenc;Ray E Hershberger;Peter S Streyger;Charles T Roberts
  • 通讯作者:
    Charles T Roberts
Live‐cell imaging demonstrates rapid cargo exchange between lipid droplets in adipocytes
活细胞成像显示脂肪细胞中脂滴之间的快速货物交换
  • DOI:
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    3.5
  • 作者:
    R. Somwar;Charles T Roberts;O. Varlamov
  • 通讯作者:
    O. Varlamov

Charles T Roberts的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Charles T Roberts', 18)}}的其他基金

YR 50 PROJ- ROBERTS PRIMATE ISLET
YR 50 项目 - 罗伯茨灵长类胰岛
  • 批准号:
    8357800
  • 财政年份:
    2011
  • 资助金额:
    $ 1.11万
  • 项目类别:
MOLECULAR MECHANISMS OF HUMAN AND MURINE BETA CELL PROLIFERATION & REGENERATION
人和鼠β细胞增殖的分子机制
  • 批准号:
    8357868
  • 财政年份:
    2011
  • 资助金额:
    $ 1.11万
  • 项目类别:
HERSTATIN: A NOVEL CANCER THERAPEUTIC
赫斯汀:一种新型癌症治疗药物
  • 批准号:
    8357799
  • 财政年份:
    2011
  • 资助金额:
    $ 1.11万
  • 项目类别:
HERSTATIN: A NOVEL CANCER THERAPEUTIC
赫斯汀:一种新型癌症治疗药物
  • 批准号:
    8173287
  • 财政年份:
    2010
  • 资助金额:
    $ 1.11万
  • 项目类别:
ALOGLIPTIN EFFECTS ON PANCREATIC ISLET FUNCTION
阿格列汀对胰岛功能的影响
  • 批准号:
    8173288
  • 财政年份:
    2010
  • 资助金额:
    $ 1.11万
  • 项目类别:
YR 50 PROJ- ROBERTS PRIMATE ISLET
YR 50 项目 - 罗伯茨灵长类胰岛
  • 批准号:
    8173289
  • 财政年份:
    2010
  • 资助金额:
    $ 1.11万
  • 项目类别:
A NOVEL MECHANISM OF ANDROGEN RECEPTOR ACTION
雄激素受体作用的新机制
  • 批准号:
    7958495
  • 财政年份:
    2009
  • 资助金额:
    $ 1.11万
  • 项目类别:
A PHASE-I/II STUDY OF IMC-A12 IN CHILDREN WITH RELAPSED/ REFACTORY SOLID TUMORS"
IMC-A12 在复发/难治性实体瘤儿童中的 I/II 期研究"
  • 批准号:
    7958528
  • 财政年份:
    2009
  • 资助金额:
    $ 1.11万
  • 项目类别:
A NOVEL MECHANISM OF ANDROGEN RECEPTOR ACTION
雄激素受体作用的新机制
  • 批准号:
    7715989
  • 财政年份:
    2008
  • 资助金额:
    $ 1.11万
  • 项目类别:
WT1 P53 INTERACTIONS IN IGF I RECEPTOR REGULATION
WT1 P53 在 IGF I 受体调节中的相互作用
  • 批准号:
    2736212
  • 财政年份:
    1997
  • 资助金额:
    $ 1.11万
  • 项目类别:

相似海外基金

Variability of Brain Reorganization in Blindness
失明时大脑重组的变异性
  • 批准号:
    10562129
  • 财政年份:
    2023
  • 资助金额:
    $ 1.11万
  • 项目类别:
Beyond the Visual: Blindness and Expanded Sculpture
超越视觉:失明与扩展的雕塑
  • 批准号:
    AH/Y005856/1
  • 财政年份:
    2023
  • 资助金额:
    $ 1.11万
  • 项目类别:
    Research Grant
Innovative therapeutic strategies to support elimination of river blindness
支持消除河盲症的创新治疗策略
  • 批准号:
    10754120
  • 财政年份:
    2023
  • 资助金额:
    $ 1.11万
  • 项目类别:
Anatomical, neural, and computational constraints on sensory cross-modal plasticity following early blindness
早期失明后感觉跨模态可塑性的解剖学、神经学和计算限制
  • 批准号:
    10570400
  • 财政年份:
    2023
  • 资助金额:
    $ 1.11万
  • 项目类别:
Follow on to: Preventing avoidable blindness through smart home-monitoring of vision
继续:通过智能家居视力监测预防可避免的失明
  • 批准号:
    ES/Y001346/1
  • 财政年份:
    2023
  • 资助金额:
    $ 1.11万
  • 项目类别:
    Research Grant
Establishment of preventive methods for blindness due to pathologic myopia by targeting CCDC102B
以CCDC102B为靶点建立病理性近视致盲预防方法
  • 批准号:
    23K09009
  • 财政年份:
    2023
  • 资助金额:
    $ 1.11万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanisms of neural compensation in the retina and dysfunction in congenital stationary night blindness
先天性静止性夜盲症视网膜神经代偿机制及功能障碍
  • 批准号:
    10678730
  • 财政年份:
    2023
  • 资助金额:
    $ 1.11万
  • 项目类别:
NSF Convergence Accelerator Track H: Phase II Smart Wearables for Expanding Workplace Access for People with Blindness and Low Vision
NSF 融合加速器轨道 H:第二阶段智能可穿戴设备,扩大失明和低视力人士的工作场所使用范围
  • 批准号:
    2345139
  • 财政年份:
    2023
  • 资助金额:
    $ 1.11万
  • 项目类别:
    Cooperative Agreement
3D bioprinting of regenerative, corneal cell-laden inks to treat corneal blindness
3D 生物打印充满角膜细胞的再生墨水来治疗角膜失明
  • 批准号:
    10606474
  • 财政年份:
    2023
  • 资助金额:
    $ 1.11万
  • 项目类别:
From 'plant blindness' to 'bug blindness': disseminating an evidence-based pedagogy for plants and refining methodologies in attitudinal research
从“植物盲”到“虫盲”:传播植物循证教育学并完善态度研究方法
  • 批准号:
    ES/X007324/1
  • 财政年份:
    2022
  • 资助金额:
    $ 1.11万
  • 项目类别:
    Fellowship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了